research Severe scarring alopecia associated with combinational use of ficlatuzumab and gefitinib: a clinical and immunohistochemistry study
Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.
Search
for
Sort by
Research
90-120 / 1000+ resultsresearch Prevention of erlotinib-induced folliculitis with doxycycline
Doxycycline helps prevent skin issues from erlotinib in lung cancer patients.
research Periocular Manifestations of Afatinib Therapy
Afatinib can cause eyelash and eyebrow issues, leading to eye irritation and pain.
research Vandetanib
A man developed alopecia areata after starting cancer treatment with vandetanib.
research A phase I study of MK-5108, an oral aurora A kinase inhibitor, in both monotherapy and in combination with docetaxel in patients with advanced solid tumors.
MK-5108 is safe and shows potential against tumors, especially alone.
research Kinase Inhibition with BAY 43–9006 in Renal Cell Carcinoma
BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.
research Cutaneous adverse effects of targeted therapies
Targeted cancer therapies often cause serious skin problems that need careful management.
research Unique Cutaneous Reaction to Second- and Third-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
Certain leukemia drugs can cause severe skin reactions that may require stopping treatment.
research Medication-Induced Repigmentation of Gray Hair: A Systematic Review
Some medications might reverse gray hair, especially those that reduce inflammation or stimulate pigment production, and vitamin B might help.
research Repigmentation and new growth of hairs after anti–interleukin-17 therapy with secukinumab for psoriasis
A man's gray hair got darker and thicker after using a psoriasis drug.
research Hair Manifestations of Systemic Disease
Hair changes can indicate systemic diseases or medication effects.
research Synthesis, Anticancer and Molecular Docking Studies of 2-(4-chlorophenyl)-5-aryl-1,3,4-Oxadiazole Analogues
The compound 4c showed strong potential as an anticancer agent.
research Scalp hair repigmentation in the penumbral region of radiotherapy– a case series
Radiotherapy can cause rare changes in hair color, which should be discussed with patients.
research BH12 A case of reverse ageing phenomenon of the hair secondary to vitamin B supplementation
Vitamin B supplements may reverse grey hair.
research Premature Graying of Hair
Premature graying of hair is common and stressful, but not well understood or treated.
research P62: An increase in Breslow thickness: coronavirus or coincidence?
The pandemic likely caused delays in skin cancer assessments, leading to fewer early diagnoses and thicker melanomas.
research Sorafenib-induced Facial Acneiform Eruption
Low-dose sorafenib can cause severe facial acne, treatable with topical medication.
research Section 2: Single Best Answers Questions 51–120
The document tests knowledge and decision-making in hematology through multiple-choice questions.
research Single Best Answers
The document provides 70 multiple choice questions to improve haematology skills.
research Phase II study of safusidenib erbumine in patients with chemotherapy- and radiotherapy-naïve isocitrate dehydrogenase 1-mutated WHO grade 2 gliomas
Safusidenib erbumine shows promise as a treatment for certain brain tumors, but mild side effects like hair loss need attention.
research Two cases of alopecia areata treated with ruxolitinib: a discussion of ideal dosing and laboratory monitoring
Ruxolitinib effectively and safely regrows hair in alopecia patients.
research USE OF TOFACITINIB IN DIFFICULT TO TREAT CLINICALLY AMYOPATHIC DERMATOMYOSITIS
Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.
research Oral and Topical Janus Kinase Inhibitors in Patients With Cutaneous T‐Cell Lymphoma: A Real‐World Single‐Center Experience
Janus kinase inhibitors may help treat cutaneous T-cell lymphoma, but more research is needed.
research JAK inhibitor deuruxolitinib shows encouraging hair re-growth in alopecia areata
research Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours
The drug combination was safe and showed promise in treating advanced tumors.
research The Efficacy and Safety of Anlotinib Plus Etoposide with Cisplatin/Carboplatin in the First-Line Treatment of Lung Cancer: A Phase II Clinical Study
The treatment combination is effective and generally safe for lung cancer.
research Scalp Pustule as a Manifestation of Erlotinib-Induced Skin Toxicity: Report of Two Cases and Literature Review
Erlotinib can cause scalp pustules and hair loss, needing early treatment with antibiotics and steroids.
research P718 Observational real-world evidence on the efficacy and safety of Janus Kinase inhibitors (JAKi) in the treatment of moderate to severe Active Ulcerative Colitis (UC)
Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.
research Tyrosine Kinase Inhibitors against Cancer: Their Safety in 216 Moroccan Patients
Tyrosine Kinase Inhibitors are effective against cancer but can cause skin, digestive, and blood side effects, including hair loss.